All Resources for 'Medical, Clinical & Healthcare Services'
Accounts of women identified as drinking at ‘high risk’ during pregnancy
Drinking alcohol during pregnancy is associated with Foetal Alcohol Spectrum Disorders (FASD), and women who drink at higher levels are more likely to have a baby with FASD.
Efforts to better understand and respond to ‘high risk’ drinking...
Reducing stigma towards people living with HIV and people who inject drugs
Despite extensive evidence regarding the negative effects of stigma experienced by people living with HIV (PLHIV) and people who inject drugs within health care settings, comparatively little evidence exists regarding the effectiveness of...
Webinar on Addiction Prevention for Youth
The International Society of Substance Use Professionals (ISSUP) Indonesia and the Indonesia International Training and Treatment Centre (ITTC) together hosted the second webinar on "Addiction Prevention for Youth" on Sunday, May 21, 2023...
Indonesia's INEP Plus Online Training
ISSUP Indonesia organized the Introduction to Evidence-Based Prevention (INEP) Online Course as a national-level training in Indonesia with 17 participants. The training, conducted by Dr.dr. Kristiana Siste, SpKJ, and Dr. Elvina K...
Treatment for drug and alcohol misuse should involve families and communities
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
PMGR: Recovery Kentucky: A Successful Model of Addressing Substance Use Disorder
The May 2023 Preventive Medicine Grand Rounds (PMGR) features Recovery Kentucky, a social model program that provides housing and recovery services for rural Kentuckians dealing with substance use disorder. The program is led by the...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 24, 2023
Today, the U.S. Food and Drug Administration (FDA) approved the extended-release Brixadi (buprenorphine) subcutaneous (for use under the skin) injection to treat moderate to severe opioid use disorder...